BioNexus Gene Lab Corp. BGLC
1.39
(0.09)
(6.08%)
as of 25 Sep
- Market cap
- $4.3M
- P/E
- 0.0×
Follow BGLC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(28.35%) | (35.24%) | (36.62%) | (33.66%) | |
| (24.68%) | (30.32%) | (31.37%) | (28.38%) | ||
ROIC |
(37.43%) | (40.50%) | (43.22%) | (37.16%) | |
Return on Tangible Assets |
(35.23%) | (45.73%) | (48.60%) | (45.43%) | |
Average Days of Receivables |
66.51 | 31.90 | 15.84 | 21.68 | |
Free Cash Flow per Share |
(1.46) | (1.01) | (0.49) | (0.35) | |
Free Cash Flow |
(2.62) | (1.88) | (1.19) | (0.85) | |
Capital Expenditures |
(0.04) | (0.04) | (0.03) | (0.01) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(26.57%) | (14.53%) | (9.60%) | (7.46%) | |
Accounts Receivable Turnover |
5.85 | 6.42 | 5.32 | 2.73 | |
Accounts Payable Turnover |
0.00 | 12.25 | 6.07 | 4.60 | |
Inventory Turnover |
6.73 | 6.14 | 4.95 | 2.93 | |
Average Days of Payables |
0.00 | 0.13 | 0.17 | 1.05 | |
Days of Inventory on Hand |
45.58 | 38.96 | 53.29 | 86.95 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.60% | 0.68% | 1.00% | 1.73% | |
Selling, General and Administrative Expense of Revenue |
40.75% | 54.77% | 66.18% | 87.11% | |
Share Based Compensation of Revenue |
0.00% | 13.29% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.12 | 0.62 | 0.40 | 0.33 | |
Depreciation/Fixed assets |
0.11 | 0.11 | 0.11 | 0.11 | |
Capex/Depreciation |
(0.24) | (0.22) | (0.16) | (0.04) | |
Revenue per Share |
5.27 | 4.00 | 2.20 | 1.29 | |
Operating CF per Share |
(1.44) | (0.99) | (0.48) | (0.35) | |
Capex per Share |
(0.02) | (0.02) | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Net Profit Margin |
(24.27%) | (40.20%) | (54.70%) | (82.36%) |
Columns are period end dates